Eyre TA, Kirkwood AA, Wolf J, Hildyard C, Mercer C, Plaschkes H, Griffith J, Fields P, Gunawan A, Oliver R, Booth S, Martinez-Calle N, McMillan A, Bishton M, Fox CP, Collins GP, Hatton CSR. [2-4] Examples of such dismal outco… Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes EA, McMillan A, Ardeshna KM, Jack A, Smith P, Mouncey P, Pocock C, Radford JA, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D. Ann Oncol. Get the latest public health information from CDC: https://www.coronavirus.gov. Complementary & Alternative Medicine (CAM), Coping with Your Feelings During Advanced Cancer, Late Effects of Childhood Cancer Treatment, Tech Transfer & Small Business Partnerships, Frederick National Laboratory for Cancer Research, Milestones in Cancer Research and Discovery, Step 1: Application Development & Submission, Supportive & Palliative Care Editorial Board, Levels of Evidence: Supportive & Palliative Care, Levels of Evidence: Screening & Prevention, Levels of Evidence: Integrative Therapies, U.S. Department of Health and Human Services. [Epub ahead of print] A systematic review of the efficacy of CNS prophylaxis with stand-alone Yhim HY, Yoon DH, Kim SJ, Yang DH, Eom HS, Kim KH, Park Y, Kim JS, Kim HJ, Suh C, Kim WS, Kwak JY. -. Wilson MR, Eyre TA, Martinez-Calle N, Ahearne M, Parsons KE, Preston G, Khwaja J, Schofield J, Elliot J, Mula Kh A, Shah N, Cheung CK, Timmins MA, Creasey T, Linton K, Smith J, Fox CP, Miall F, Cwynarski K, McKay P. Blood Adv. Epub 2019 Jun 20. Copyright© 2020 Ferrata Storti Foundation. NLM 2017 Oct 1;28(10):2511-2516. doi: 10.1093/annonc/mdx353. NCI's Dictionary of Cancer Terms provides easy-to-understand definitions for words and phrases related to cancer and medicine. NIH 73% developed isolated CNS relapses, 24% concurrent CNS/systemic relapse, and 3% post-systemic relapse. In this review, we outline different strategies of administering CNS prophylaxis in DLBCL patients reported in literature and discuss their advantages and drawbacks. National Center for Biotechnology Information, Unable to load your collection due to an error, Unable to load your delegates due to an error. 2017; 75:195-203. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): Pre- and post-rituximab. 2016;34(26):3150-3156. Use of CNS-penetrating intravenous antimetabolite or purine analogue therapy (methotrexate or cytarabine) has … Intrathecal chemotherapy with methotrexate has long been a component of CNS prophylaxis and is beneficial in patients with testicular lymphoma. Eur J Cancer. We found no strong evidence for the benefit, or indeed genuine lack of benefit, of stand-alone intrathecal prophylaxis in preventing CNS relapse in diffuse large B-cell lymphoma-treated patients using anthracycline-based immunochemotherapy. 2011; 90(7):809-818. ‘Prophylaxis’ is a treatment that is designed to prevent something. | A systematic review of prospective studies. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multi-center study of 1532 patients treated with chemoimmunotherapy. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Many chemotherapy regimens(combinations of drugs; for example CHOP) do not reach the CNS. 7,357 rituximab/obinutuzumab-exposed patients were analysed. -, Schmitz N, Zeynalova S, Nickelsen M, et al. Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. r However in other forms of DLBCL efficacy of IT MTX appears to provide little benefit. Three post hoc analyses (RICOVER-60, RCHOP-14/21, GOYA), one prospective database and 10 retrospective series were included. There is no agreed standard approach to CNS prophylaxis. COVID-19 is an emerging, rapidly evolving situation. 2018;7(3):539-548. -, Ghose A, Elias HK, Guha G, Yellu M, Kundu R, Latif T. Influence of rituximab on central nervous system relapse in diffuse large B-cell lymphoma and role of prophylaxis. No systematic review analysing the evidence for stand-alone intrathecal prophylaxis has been performed in the era of anti-CD20 monoclonal antibody therapy.